Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris

This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.

Inclusion Criteria:

• Males and females 12 years and older
• Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria:

• Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.)
• Active facial cysts or any nodulocystic lesions